KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to 46.15%.

  • Eli Lilly's EBITDA Margin rose 67100.0% to 46.15% in Q4 2025 from the same period last year, while for Dec 2025 it was 44.82%, marking a year-over-year increase of 89000.0%. This contributed to the annual value of 44.82% for FY2025, which is 89000.0% up from last year.
  • As of Q4 2025, Eli Lilly's EBITDA Margin stood at 46.15%, which was up 67100.0% from 45.57% recorded in Q3 2025.
  • Over the past 5 years, Eli Lilly's EBITDA Margin peaked at 46.15% during Q4 2025, and registered a low of 21.46% during Q2 2021.
  • Over the past 5 years, Eli Lilly's median EBITDA Margin value was 31.29% (recorded in 2021), while the average stood at 32.62%.
  • Per our database at Business Quant, Eli Lilly's EBITDA Margin tumbled by -99300bps in 2023 and then skyrocketed by 115000bps in 2025.
  • Quarter analysis of 5 years shows Eli Lilly's EBITDA Margin stood at 29.44% in 2021, then decreased by -3bps to 28.44% in 2022, then rose by 13bps to 32.18% in 2023, then rose by 23bps to 39.44% in 2024, then grew by 17bps to 46.15% in 2025.
  • Its last three reported values are 46.15% in Q4 2025, 45.57% for Q3 2025, and 45.13% during Q2 2025.